Martin Shkreli refuses to testify, still infuriates with a smile

WASHINGTON -- Pharmaceutical chief Martin Shkreli refused to testify Thursday in an appearance before U.S. lawmakers over severe hikes for a drug sold by a company that he acquired, yet even without answering questions, managed to leave them infuriated.

See Full Article

Shkreli appeared to smirk throughout his hour-long appearance, and moments afterward, insulting tweets began to appear under his official account calling the lawmakers "imbeciles."

Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 per cent, exercised his Fifth Amendment right against self-incrimination when he went before the House Oversight and Government Reform Committee.

Four times the brash entrepreneur and former hedge fund manager -- who has been unapologetic about the price hikes, intoned before the committee, "On the advice of counsel I invoke my Fifth amendment privilege against self-incrimination and respectfully decline to answer your question."

Lawmakers erupted in fury. Rep. Elijah Cummings of Maryland, the top Democrat on the committee, told the 32-year-old Shkreli to wipe the smirk off his face.

"I call this money blood money ... coming out of the pockets of hardworking Americans," he said, as Shkreli sat through the lecture. "I know you are smiling, but I am very serious, sir," Cummings said. "I truly believe you can become a force of tremendous good. All I ask is that you reflect on it. No, I don't ask, I beg that you reflect on it. "

Shkreli was dismissed less than an hour into the hearing, but not before Chairman Rep. Jason Chaffetz, R-Utah. shouted down a request by Shkreli's attorney to speak. Lawmakers, instead, took turns denouncing his conduct and attitude.

Minutes after Shkreli walked out of the room on his official Twitter account appeared the message, "Hard to accept that these imbeciles represent the people in our government."

Hard to accept that these imbeciles represent the people in our government.

— Martin Shkreli (@MartinShkreli) February 4, 2016

It could not immediately be confirmed if those tweets were written by Shkreli.

Cummings, attributing them to Shkreli, boiled over. "There are very real issues for people with compromised immune systems," he thundered as he asked Turing executive Nancy Retzlaff to interpret the messages on Shkreli's Twitter account.

Shkreli faces separate criminal charges of securities fraud in connection with another drug company he owned

The lawmakers had summoned him to answer for the decision that made him infamous: raising the price for Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection.

Shkreli, who pleaded not guilty after his arrest in December in New York, has been out on $5 million bail. He walked into the packed hearing room well before the session began and met the crush of cameras. Even a few members of the House panel were swept up in the curiosity and snapped Shkreli's photo on their cellphones.

Also appearing before the lawmakers was Turing's chief commercial officer and the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals. Documents from Valeant and Turing show they have made a practice of buying and then dramatically raising prices for, low-cost drugs given to patients with life-threatening conditions including heart disease, AIDS and cancer, according to excerpts released this week by the House panel.

The two companies' executives insisted they were committed to ensuring that cost isn't a deterrent for patients who need the drugs.

With Shkreli mum, it was up to Retzlaff to defend the Daraprim price rise. She said about 3,000 people are treated by Daraprim, and only 25 per cent are covered by commercial insurance. She added that the overall impact of the drug on the budget of commercial health plans "is very, very small."

Documents show how executives at both companies planned to maximize profits while fending off negative publicity over the price hikes.

Presentations by Turing executives, part of the trove of documents obtained by the panel., show that as early as last May, the company planned to turn Daraprim into a $200-million-a-year drug by dramatically increasing its price. Turing bought the 60-year-old drug from Impax Laboratories in August for $55 million and swiftly raised its price.

Shkreli said in an email to one contact: "We raised the price from $1,700 per bottle to $75,000. Should be a very handsome investment for all of us."

But anticipating a possible backlash, the company warned in an internal memo that advocates for HIV patients might react to the price hike.

Valeant likewise identified revenue goals first and then used drug prices to reach them, committee staff said in a memo. It said Valeant believed it could repeatedly raise the prices of Nitropress and Isuprel without repercussions because they're administered by hospitals, which are less price-sensitive than consumers.

Valeant used patient assistance programs to distract attention and justify its price hikes, according to the memo.

AP Business Writer Tom Murphy in Indianapolis contributed to this report



Advertisements

Latest Economic News

  • Consumer debt and delinquency rates climb in third quarter: Equifax

    Economic CTV News
    TORONTO - A new Equifax Canada report says low interest rates and falling oil prices drove up consumer debt and delinquency rates in the third quarter. The credit reporting agency found that average debt increased by 3.6 per cent to $22,081 in the quarter ended Sept. Source
  • Bank of Canada to make final interest rate announcement of the year

    Economic CTV News
    OTTAWA - The Bank of Canada is set to make its last interest rate announcement of the year today. The central bank is widely expected to keep its interest rate target set at 0.5 per cent, where it has been since July 2015. Source
  • Asian stocks mostly higher on record Dow, telecom news

    Economic CTV News
    TOKYO -- Asian markets were mostly higher Wednesday, cheered by gains on Wall Street and optimism about the telecommunications industry. KEEPING SCORE: Japan's benchmark Nikkei 225 rose 0.5 per cent to 18,454.92 in morning trading. Source
  • Mother settles JetBlue lawsuit after son flown to wrong city

    Economic CTV News
    NEW YORK -- A New York City woman has agreed to settle her lawsuit against JetBlue Airways after it mixed up her 5-year-old son with another boy and flew him to the wrong city. Maribel Martinez's lawyer announced the settlement on Tuesday, saying the matter was resolved amicably. Source
  • Apple pays US$450,000 for alleged hazardous waste violations

    Economic CTV News
    SAN FRANCISCO -- Apple is paying $450,000 to settle allegations that the iPhone maker operated and closed two hazardous-waste processing plants without submitting the proper paperwork to California environmental regulators. The agreement announced Tuesday involves a now-closed plant near Apple's Cupertino, California, headquarters and another one in nearby Sunnyvale. Source
  • Alaska Airlines gets U.S. approval to buy Virgin America

    Economic CTV News
    WASHINGTON -- Alaska Airlines has won government approval to buy rival Virgin America after agreeing to reduce its flight-selling partnership with American Airlines. Parent company Alaska Air Group Inc. said Tuesday that it expects to close the $2.6 billion deal soon. Source
  • Trump calls for cancellation of Air Force One replacement order with Boeing

    Economic CBC News
    A tweet from president-elect Donald Trump calling on the U.S. government to scrap an order with Boeing Co. for the development of a replacement for the Air Force One jet temporarily knocked about $1 billion US off the stock market value of the aircraft maker. Source
  • Ont. company fined $225K for ozone-harming chemical

    Economic CTV News
    BRAMPTON, Ont. -- A company in Mississauga, Ont., has been fined $225,000 for importing and selling chemicals that harm the ozone layer. The federal government says CRC Canada pleaded guilty to two counts under the Canadian Environmental Protection Act. Source
  • Alberta nosedives on global oil and gas investment ranking

    Economic CBC News
    Alberta has plunged to 43rd place in its attractiveness to global oil and gas investors, a report by the Fraser Institute suggests. The 10th annual Global Petroleum Survey of industry executives looks at various jurisdictions around the globe and a variety of barriers that might impact investment decisions in key oil and gas producing regions. Source
  • High court sides with Samsung in patent dispute with Apple

    Economic CTV News
    WASHINGTON -- The Supreme Court unanimously sided with smartphone maker Samsung on Tuesday in its high-profile patent dispute with Apple over design of the iPhone. The justices said Samsung may not be required to pay all the profits it earned from 11 phone models because the features it copied from the iPhone were only a part of Samsung's devices. Source